Intellia Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- John Leonard
- Full Time Employees
- 377
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 40 Erie Street Cambridge MA United States of America 02139
- IPO Date
- May 6, 2016
- CIK
- 0001652130
- Website
- intelliatx.com
- Similar Companies
- Business
- Intellia Therapeutics, Inc. Intellia Therapeutics, Inc. (NTLA) is a clinical-stage biotechnology company focused on developing potentially curative CRISPR/Cas9-based gene editing therapeutics for severe genetic diseases, cancers, and autoimmune disorders; its core pipeline includes nexiguran ziclumeran (nex-z, formerly NTLA-2001) in Phase 3 trials for transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN) and cardiomyopathy (ATTR-CM), lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) in Phase 3 HAELO trial for hereditary angioedema (HAE) with topline data expected mid-2026, NTLA-3001 for ATTR amyloidosis, NTLA-4001 for T-cell malignancies, and research programs in hemophilia B (partnered with Regeneron Pharmaceuticals, Inc.), hematological disorders such as sickle cell disease and beta-thalassemia, as well as immuno-oncology and autoimmune disease targets. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company leverages a modular gene editing platform for in vivo and ex vivo therapies, supported by collaborations including Regeneron for ATTR amyloidosis co-development and cost reimbursements. Recent developments encompass completion of enrollment in the Phase 3 HAELO trial for lonvo-z in September 2025 ahead of schedule, presentation of positive longer-term Phase 1/2 data for nex-z and lonvo-z at ACAAI 2025 and other conferences, advancement in the Phase 3 MAGNITUDE trial for ATTR-CM, a strategic reorganization in early 2025 to prioritize late-stage programs, inducement equity grants under the 2024 Inducement Plan to support expansion, and a cash position of approximately $670 million as of Q3 2025 expected to fund operations into mid-2027 including potential U.S. commercial launch of lonvo-z in H1 2027.
Company News
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference
Bank of New York Mellon Corp Makes New $6.95 Million Investment in Intellia Therapeutics, Inc. $NTLA
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
Intellia Therapeutics Q2 Earnings Call Highlights
Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Hold” by Brokerages
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
Amova Asset Management Americas Inc. Reduces Stake in Intellia Therapeutics, Inc. $NTLA
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze